Navigation Links
BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
Date:11/26/2013

and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in early 2014; BL-8040 for treating acute myeloid leukemia (AML) and other hematological indications, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Various statements in this release concerning BioLineRx's future expectations, including specifically those related to the development and commercialization of BL-7040, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include words such as "may," "expects," "anticipates," "believes," and "intends," and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of BioLineRx to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technologi
'/>"/>

SOURCE BioLineRx
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
2. BioLineRx Reports Third Quarter 2013 Financial Results
3. BioLineRx to Report Third Quarter 2013 Results on November 13, 2013
4. BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
5. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
6. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
7. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
8. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
9. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
10. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
11. BioLineRx to Present at 15th International Celiac Disease Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... VIEW, Calif., Feb. 10, 2011 ZONARE Medical Systems, ... z.one Ultrasound System to Woodlands Church of Plover, WI, ... the past year, ZONARE has provided six systems to ... and medical missions. Woodlands Church performs annual ...
... AlphaDetail, a leader in global primary market research for ... in revenue in 2010, exceeding $18.5M in annual revenue ... "Our clients have delivered a loud and clear ... get at the heart of their strategic information needs," ...
Cached Medicine Technology:ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 2ZONARE Provides z.one Ultrasound System for Medical Missions to Guatemala 3AlphaDetail Revenue Soars 30% in 2010 2
(Date:7/9/2014)... in policing injection drug users in Russia might ... , A study, conducted by researchers from Boston ... collaboration with St. Petersburg Pavlov State University, sought ... the health outcomes of a cohort of HIV-positive ... Those who were arrested by police were more ...
(Date:7/9/2014)... (July 8, 2014) Researchers from Montefiore Medical ... Medicine of Yeshiva University will present new findings ... July 12 July 17 in Copenhagen, Denmark. Data ... could prompt transition from cognitive normality to mild cognitive ... Einstein Aging Study , established in 1980 to ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... July 9, 2014 A study published in the ... Koninck and Robert Bonin, two researchers at Universit Laval, ... using a new method that involves rekindling pain so ... lead to novel means to alleviate chronic pain. , ... Laval and Institut universitaire en sant mentale de Qubec ...
(Date:7/8/2014)... Department of Defense,s Defense Advanced Research Projects Agency ... to $2.5 million to develop an implantable neural ... neurons within the brain to help restore memory, ... builds on the understanding that memory is a ... the brain encode information, store it and retrieve ...
Breaking Medicine News(10 mins):Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... 28 Ronald McDonald House Charities of,the New York ... local graduating high school seniors. Students in the New,York, ... an application at www.rmhc.org or call 1-866-851-3994. ... "The RMHC U.S. Scholarship Program ...
... has halved the number of infants born with Down,s ... birth by 30%, according to a study published on ... Australia and New Zealand, are trying to introduce national ... variety of problems because of a lack of consensus ...
... appear even in the presence of disinfecting solutions , , THURSDAY, ... lens storage cases, say Israeli researchers who found at least ... 16 people. , The tests of contact lens disinfection solution ... a known cause of severe corneal infections -- was the ...
... The Committee for Human,Medicinal Products (CHMP) has ... dosing of 800 mg PREZISTA(R) (darunavir) with ... treatment-naive adults (those who,have never taken HIV ... by Tibotec Pharmaceuticals, and Tibotec, a division ...
... Nov. 27 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... and medical device,research and development outsourcing company with ... Edward Hu, the Company,s Chief Operating,Officer, will present ... Wednesday, December 3, 2008, at 12:00 pm Eastern ...
... 26 /PRNewswire-USNewswire/ -- The Pennsylvania Department of ... outpatient, emergency and non-emergency admissions to Commonwealth Medical Center, ... , The department said ... management addresses non-compliance with licensing standards which pose a ...
Cached Medicine News:Health News:Ronald McDonald House Charities(R) of the New York Tri-State Area to Award Over $500,000 in Scholarships to Graduating High School Seniors 2Health News:New screening halves the number of children born with Down syndrome 2Health News:Contact Lens Cases Often Contaminated 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 2Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 3Health News:European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA(R) (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1 4Health News:WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference 2
... nebulizer achieves optimum lung penetration for maximum ... is 1.04-1.10 µ at 6-8 LPM. Latex-free ... ,As the world leader in airway ... assurance of proven technology by offering top ...
... OMNI~NEB delivers breakthrough continuous low-flow nebulizer ... precise nozzle technology allows for optimal ... or without Heliox). OMNI~NEB takes on ... both routine and critical care situations. ...
... a spill-proof design and effective output, even ... All medical nebulizers are free-standing for easy ... are available., ,All Portex® medication nebulizer ... nebulizers feature consistently fine misting and the ...
... Portex® medication nebulizers offer a spill-proof ... up to a 45° angle. All medical ... ,A wide variety of configurations are available., ... latex-free. , ,Portex® medication nebulizers feature ...
Medicine Products: